April 29 marks a pivotal second in most cancers analysis when the world’s brightest minds come collectively to debate the right way to translate the success of CAR T-cell therapies for blood cancers into profitable cell and gene therapies for probably the most advanced and lethal strong tumor cancers.
The scientists and firms driving the most recent advances in most cancers cell and gene remedy will collect on-line for a digital Summit with the Alliance for Most cancers Gene Remedy, who envision a most cancers free future and need to change the C-word from Most cancers to Remedy. The Summit is open to the general public, to medical professionals, scientists and firms serious about cell and gene remedy to battle most cancers. To register for the Summit, go to acgtfoundation.org.
Summit 2021 is being held on-line on Thursday, April 29, 2021, from 10:00 a.m. till 6:00 p.m (ET), and options eight (8) panel discussions with main researchers creating the subsequent era most cancers cell and gene therapies, biotech corporations who’re bringing new therapies by the clinic, and traders who’re funding this burgeoning pipeline of strong tumors breakthroughs.
The panels embody:
Keynote: Does Most cancers Have a Future? What’s Subsequent? The place Will We Be in 2025?
A dialog with Nobel Laureate James P. Allison, PhD, government director of the Immunotherapy Platform at MD Anderson Most cancers Middle, and Carl H. June, MD, director of the Middle for Mobile Immunotherapies, Perelman College of Drugs, College of Pennsylvania. The dialog shall be moderated by Siddhartha Mukherjee, MD, founder, Myeloid Therapeutics, Pulitzer-prize profitable creator of “The Emperor of All Maladies.”
Evolving Cell and Gene Regulatory and Manufacturing Processes to Match the Velocity of Innovation
Panel dialogue with: Rafael Amado, MD, government vice chairman, head of R&D and chief medical officer, Allogene Therapeutics; Andre Choulika, PhD, chairman, CEO and founder, Cellectis; Amy DuRoss, founder and CEO, Vineti; Bruce Levine, PhD, Barbara and Edward Netter professor in Most cancers Gene Remedy, College of Pennsylvania; Ke Liu, MD, PhD, senior vice chairman and head of Regulatory Affairs & Technique at Sana Biotechnology, former FDA Oncology Middle of Excellence affiliate director for Cell and Gene Remedy; and moderated by Asthika Goonewardene, managing director, Fairness Analysis – Biotech, Truist Securities.
Innovating Science, From the Lab to the Clinic
Panel dialogue with: Brian Brown, PhD, professor and affiliate director of the Precision Immunology Institute, Icahn College of Drugs, Mount Sinai; Yvonne Chen, PhD, affiliate professor of Microbiology, Immunology & Molecular Genetics, UCLA, Founder Kalthera; Franco Marincola, PhD, senior vice chairman and international head of Cell Remedy Analysis at Kite, a Gilead Firm; Clodagh O’Shea, PhD, professor, Molecular and Cell Biology Laboratory, Salk Institute, scientific founder IconOVir Bio; and moderated by Jenna Foger, senior vice chairman, Science & Expertise, Alexandria Enterprise Investments/Alexandria Actual Property Equities.
Tackling the Hardest Challenges — Pancreatic Most cancers
Panel dialogue with: Sidi Chen, PhD, affiliate professor, Yale Most cancers Middle; Joseph A. Fraietta, PhD, director, Strong Tumor Immunotherapy Laboratory, Middle for Superior Mobile Therapeutics, College of Pennsylvania; Michael T. Lotze, MD, professor of Surgical procedure and Bioengineering, College of Pittsburgh, chief mobile officer, Nurix, chair of Alliance for Most cancers Gene Remedy’s Scientific Advisory Council; Mark H. O’Hara, PhD, assistant professor of Drugs on the Hospital of the College of Pennsylvania; and moderated by Andrew Rakeman, PhD, vice chairman of Analysis, Lustgarten Basis.
Tackling the Hardest Challenges — Glioblastoma
Panel dialogue with: Nduka Amankulor, MD, division of Neurosurgery, College of Pittsburgh Medical Middle; Samantha Bucktrout, PhD, senior director of Analysis, Parker Institute of Most cancers Immunotherapy; Noriyuku Kasahara, MD, PhD, principal investigator, Mind Tumor Middle, UCSF; Crystal Mackall, MD, founding director, Stanford Middle for Most cancers Cell Remedy; and moderated by Klaus Veitinger, MD, PhD, enterprise accomplice OrbiMed.
New Approaches to Strong Tumor Breakthroughs
Panel dialogue with: Ken Drazan, MD, chief government officer, ArsenalBio; Daniel Getts, PhD, chief government officer & co-founder, Myeloid Therapeutics; Garry E. Menzel, PhD, president and chief government officer at TCR² Therapeutics; and moderated by Luke Timmerman, founder and editor, The Timmerman Report.
Sufferers, Caregivers, Medical doctors, Oncologists, Advocates, Researchers, You, Me – All of us Have Most cancers in Frequent
Panel dialogue with: Caroline Nook, PhD, managing director, Westwicke; Robert Levis, director CLL Society; Callum Miller, CAR-T recipient, affected person advocate; Tom Whitehead, co-founder, The Emily Whitehead Basis; and moderated by Gregory C. Simon, former president of the Biden Most cancers Initiative.
Innovating Finance, Non-Conventional Funding Sources
Panel dialogue with: Jay Campbell, managing director of Most cancers Analysis Institute Scientific Accelerator and Enterprise Fund; Marc Hurlbert, PhD, chief science officer, Melanoma Analysis Alliance; Ken Schaner, accomplice Schaner & Lubitz; Anna Turetsky, PhD, principal, Enterprise Investments, The Mark Basis for Most cancers Analysis; moderated by Luke Evnin, PhD, co-founder and managing director MPM Capital.
It is so uncommon to have the chance to listen to from the world’s high most cancers researchers, biotechs, traders and sufferers all in the identical room. We’re excited to have Alliance for Most cancers Gene Remedy be a catalyst for these essential conversations that can assist not solely different scientists engaged on new cell and gene remedy approaches, however corporations looking for funding to advance their medical pipelines, and sufferers and their households searching for doubtlessly life altering therapeutic choices of their battle towards most cancers.”
Barbara Lavery, hief program officer for Alliance for Most cancers Gene Remedy.